 SEATTLE, July 07, 2021 GLOBE NEWSWIRE -- Chinook Therapeutics, Inc. Nasdaq: KDNY, a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation Committee of the Companys Board of Directors approved a new employment inducement grant of stock options to purchase 25,733 shares of common stock with a grant date of June 30, 2021 the Inducement Grants for a new employee. 